Hormonal Contraceptives Safe After Complete Hydatidiform Mole
HC use doesn't increase risk of gestational trophoblastic neoplasia regardless of hCG level
FRIDAY, Oct. 16, 2015 (HealthDay News) -- The use of current hormonal contraceptives (HC) can safely prevent new conception after complete hydatidiform mole (CHM) irrespective of human chorionic gonadotropin (hCG) level, according to a study published online Oct. 7 in BJOG: An International Journal of Obstetrics and Gynaecology.
A. Braga, from the Maternity School of Rio de Janeiro Federal University, and colleagues conducted a historical database review to re-evaluate the safety of HC after uterine evacuation of CHM. They examined time to hCG remission for 2,423 women with CHM, of whom 154 commenced HC while their hCG was still elevated. They also assessed the correlations between HC use and gestational trophoblastic neoplasia (GTN) development and high International Federation of Gynecology and Obstetrics (FIGO) risk score.
The researchers found that there was no correlation between HC use and mean time to hCG remission (12 weeks for both HC users and nonusers; P = 0.19). There was also no correlation seen for HC use with GTN development (HC users versus nonusers: 20.1 and 16.7 percent; P = 0.26) or high FIGO risk score (HC users versus nonusers: 0 and 8 percent; P = 0.15 percent). Even when an age-adjusted model was used, there was no correlation between HC and GTN development (odds ratio, 1.37; 95 percent confidence interval, 0.91 to 2.08; P = 0.13).
"HC can be safely used to prevent a new conception following CHM regardless of hCG level," the authors write.